Organon & Co. 4

Head of R&D & CMO Juan Camilo Arjona Ferreira had 11,519 RSUs convert into common stock and sold 4,134 Organon & Co. (OGN) shares, primarily in connection with equity award vesting.

On August 11, 2026, Organon & Co. Head of R&D & CMO Juan Camilo Arjona Ferreira had 11,519 restricted stock units convert into an equivalent number of common shares and, in a related transaction, disposed of 4,134 shares at $13.62 per share, most likely to cover withholding taxes, resulting in a modest net increase in his direct common stock ownership to 37,432.477 shares and leaving 11,519 RSUs outstanding that will vest in three equal installments through August 11, 2026. Based on the current share price of approximately $13.68, his post-transaction common stock holdings are worth roughly $512,000, while the newly-awarded/remaining RSUs represent an additional stake of about $158,000, indicating routine equity compensation activity rather than an open-market purchase or discretionary sale.

Filing Facts

CIK

1821825

Ticker

OGN

Form

4

Source Type

fda

Accession

0001628280-26-056061

Alert Tier

5